Displaying items by tag: healthcare
Healthcare has been one of the predominant stories of the pandemic, but its stock prices…see the full story on our partner Magnifi’s site
Vertex Pharmaceuticals was a shining star amongst the already bright biotech industry. In the nearly decade-long stretch…See the full story on our partner Magnifi’s site
The multinational biopharmaceutical company Amgen has agreed to terms to acquire Five Prime Therapeutics Inc. Amgen aims to improve its portfolio of…view the full story on our partner Magnifi’s site
Because of how the polls are trending, very few seem to be thinking about the fact that a Republican sweep of all three chambers of the government could happen. When you step away from the polls and think about the fact that Republicans currently control two of the three chambers, it becomes more realistic; and even more so when you consider that polls are likely skewed towards Democrats because of “silent” Republican supporters. If the Republicans sweep, or even just if Trump wins, then the sectors that will surge are energy, banks, healthcare, and defense. In particular, think names like Marathon Petroleum, Bank of America, Pfizer, and Northrop Grumman.
FINSUM: This may be unlikely, but it is not as wildly unrealistic as some make it sound. Perhaps smart to have a portion of the portfolio in these sectors headed into the election?
In what seems one of the most predictable outcomes of the Coronavirus pandemic, asset managers have decided to pounce and launch virus-specific ETFs. Pacer ETFs has just launched the Pacer BioThreat ETF (ticker: VIRS, of course), which tracks a custom index which follows “U.S.-listed stocks of companies that help protect against or recover from biological threats to human health based on a proprietary, multi-step research process”. Other providers, such as EQM, are doing the same.
FINSUM: This is not as gimmicky as it sounds. Companies that have businesses that benefit from coronavirus are going to be a sustained investment focus for some time.